Could a common diabetes drug boost brain power in schizophrenia?
NCT ID NCT05838573
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study tested whether metformin, a drug used for diabetes, can improve cognitive problems in people with schizophrenia. 120 participants took either metformin or a placebo for 24 weeks. Researchers measured changes in thinking skills and brain scans to see if metformin helps.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- metformin
- What this could lead to
- If it works, this could point toward a new way to help with thinking and memory problems in people with schizophrenia.
- What could go wrong
- This is a completed phase 3 trial, but results are not yet reported. Metformin is generally safe, but it may not improve cognition, and the effect may be small.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
120 people
The number who actually took part.
- Started
-
May 2023
- Finished
-
Jun 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male and female aged 18 to 50 years, who meet the Diagnostic and Statistical Manual (DSM-5) diagnostic criteria for schizophrenia. 2. Duration of illness less than 15 years with current symptoms in a stable condition. 3. Participants must be receiving stable treatment with standard-of-care medications, with a maximum allowance of two antipsychotic medications. If additional anticholinergic agents are required for the management of extrapyramidal symptoms, they should be prescribed at low dosages. 4. Have great compliance with medication and follow-up. 5. Meet one of the diagnostic criteria for metabolic syndrome: 1)abdominal obesity (i.e. central obesity): waist circumference for male≥90 cm, for female ≥85 cm; 2)fasting blood glucose ≥110 mg/dl (6.1 mmol/l) and/or plasma glucose ≥140 mg/dl (7.8 mmol/l) after glucose load; 3)at fasting state, triglyceride ≥1.7 mmol/l; 4)at fasting state, HDL-C \<1.04 mmol/L. 6. Signed the study consent for participation. Exclusion Criteria: 1. Having a history of substance dependence or abuse or whose symptoms are caused by other diagnosable mental disorders. 2. Having a history of traumatic brain injury, seizures or other known neurological or organic diseases of the central nervous system. 3. Taking antidepressants, stimulants, mood stabilizers or accepts electricity shock treatment. 4. Having current suicidal or homicidal thoughts or any safety concern by research staff that cannot be managed in an inpatient setting. 5. Taking dementia related drugs, minocycline, and other drugs that could affect cognitive function. 6. The routine blood tests showing significant abnormal renal, liver function or other somatic disease. 7. Pregnant or lactating women. For schizophrenic participants who don't meet any of the diagnostic criteria for metabolic syndrome will only accept baseline evaluations.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mental Health Institute of Second Xiangya Hospital,CSU
Changsha, Hunan, 410011, China
-
Shandong Mental Health Center
Jinan, Shandong, 250014, China
-
The Second People's Hospital of Dali Bai Autonomous Prefecture
Dali, Yunnan, 671014, China
-
The Third Peoples's Hospital of Jiangyin
Jiangyin, Jiangsu, 214400, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia